Ossur North America Company Profile

07:37 EDT 22nd June 2018 | BioPortfolio

Our work is as much about people as it is about products. Our goal is their comfort, confidence and rehabilitation - helping them to lead a life without limitations. We never forget that every time we develop a product or service, we are helping someone else to build a better life. And we couldn't think of a better business to be in. It is advancements in technology and the ability to improve people's lives that inspire us to strengthen partnerships with practitioners and design the most innovative orthopaedic products and services.
Named by the World Economic Forum as a "Technology Pioneer" for 2006, we are proud to be at the forefront of a new era in orthopaedic design and functionality. We have some of the brightest minds working on the smartest concepts. Our objectives are simply to eliminate the physical limitations caused by certain disabilities and make the technology available to a wider group of people.
Delivering those objectives is a more challenging affair. However, with the help of our partners, customers, investors and the users of our products, that's exactly what we intend to do. We look forward to your company on this important journey.


27412 Aliso Viejo Pkwy
Aliso Viejo
United States of America


Phone: 800 233 6263

News Articles [2031 Associated News Articles listed on BioPortfolio]

Global and North America Orthopedic Orthotics Market Status and Future Forecast 20132023 [Report Updated: 26012018] Prices from USD $2500

SummaryKey Content of Chapters Including and can be customizedPart 1:Market Overview, Development, and Segment by Type, Application RegionPart 2:Global Market by company, Type, Application RegionPar...

Ossur Hf : Q4/FY 2017 Results - Conference call Tuesday 6 February at 9:00 CET

Announcement from Össur hf. no: 4/2018 Conference call on Tuesday 6 February at 9:00 CET / 8:00 GMT / 3:00 EDT After market closing on Monday 5 February, Össur will publish its financial res...

Ossur Hf : Q1 2018 Results - Conference call Thursday 26 April at 9:00 CET

Announcement from Össur hf. no: 28/2018 Conference call on Thursday 26 April at 9:00 CET / 7:00 GMT / 3:00 EDT After market closing on Wednesday 25 April, Össur will publish its financial r...

Ossur Hf : Board decisions following the Annual General Meeting

Announcement no. 18/2018Reykjavik, 8 March 2018  Board decisions following the Annual General Meeting Enclosed are the Board decisions following the Annual General Meeting of Össur hf. held...

Ossur Hf : Share buy-back of 1,478,700 own shares

Announcement no. 21/2018 Reykjavik, 13 March 2018  Share buy-back of 1,478,700 own shares Today, Össur purchased 1,478,700 own shares at the price of DKK 28.10 per share. The total purchase pr...

Ossur Hf : New share option program

Announcement no. 19/2018Reykjavik, 8 March 2018  New share option program Enclosed information on a new share option program for the CEO and other members of the Executive Management, thei...

Ossur Hf : Registration of capital reduction of 6,354,662 shares completed

Announcement no. 24/2018Reykjavik, 27 March 2018  Registration of capital reduction of 6,354,662 shares completed Reference is made to the Company's announcement no. 17/2018 published on ...

Ossur Hf : Annual General Meeting 8 March 2018

Announcement no. 10/2018Reykjavik, 15 February 2018  Össur hf. - Annual General Meeting 8 March 2018 Össur hf.'s Annual General Meeting will be held on Thursday, 8 March 2018...

PubMed Articles [1281 Associated PubMed Articles listed on BioPortfolio]

First report of the post-fire morel Morchella exuberans in eastern North America.

Reports of true morels (Morchella) fruiting on conifer burn sites are common in western North America where five different fire-adapted species of black morels (Elata Clade) have been documented based...

Recovery practices in Division 1 collegiate athletes in North America.

Establish current practice and attitudes towards recovery in a group of Division-1 Collegiate athletes from North America.

Fellows' perspective of HPB training programs in North America: results of a survey.

Sixteen hepatopancreatobiliary fellowship programs in North America are accredited by the Fellowship Council. This study aims to assess fellows' perceptions of their training program.

Lost and found: the Bermudan Donadinia seaveri found in North America, with comments on its juniper associates.

Collections of a species referred to Sarcosomataceae (Pezizomycetes) from eastern North America were studied both morphologically and using nuc rDNA internal transcribed spacer (ITS) region (ITS1-5.8S...

The Paleo-Indian Entry into South America According to Mitogenomes.

Recent and compelling archaeological evidence attests to human presence ∼14.5 thousand years ago (Kya) at multiple sites in South America and a very early exploitation of extreme high-altitude Andea...

Clinical Trials [544 Associated Clinical Trials listed on BioPortfolio]

Sorafenib-RT in Treating Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. The incidence is highest in Asia and it is increasing in North America, with a two to three fold increase in mor...

Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin

This trial will be conducted in Africa, Asia, North America and South America. The aim of this clinical trial is to compare NN1250 with sitagliptin, as add-on to subject's own current oral...

Efficacy and Safety of Insulin Aspart vs. Human Insulin During Pregnancy by Women With Type 1 Diabetes

This trial was conducted in Europe, Middle East, North America and South America. The aim of this trial was to compare the use of an intensified insulin treatment Insulin Aspart (NovoRapi...

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

This trial is conducted in Europe, North America and South America. The aim of this trial is to investigate the clinical efficacy of NNC0109-0012, a human monoclonal antibody, compared to ...

CAPTAIN:Choroidal Neovascularization Assessment by Pattern Electroretinography

CNV from AMD is the leading cause of blindness in people over 50 in North America. The hypothesis is to determine if there is an improvement in retinal function determined by ERG following...

Companies [1856 Associated Companies listed on BioPortfolio]

Fagron North America

Fagron North America is a group of innovative, scientific pharmaceutical companies that focus on optimizing and innovating pharmaceutical compounding across the U.S. Fagron North ...

JMS North America Corporation

JMS North America (JMSNA) was established as a wholly owned subsidiary of JMS Co., Ltd., one of the largest Japanese medical device companies, in March 1993. Now JMSNA's headquarters is located in Hay...


Zurich in North America is a part of Zurich Financial Services Group (Zurich), an insurance-based financial services provider with a global network of subsidiaries and offices in ...

Nutricia North America

Nutricia North America, based in Rockville, Md., is a division of Danone. A leader in clinical nutrition, Nutricia North America provides medical foods and infant formulas for the...

Panasonic Healthcare Corporation of North America

Panasonic Healthcare Corporation of North America is a subsidiary of Panasonic Healthcare Co., Ltd., Tokyo, Japan, and offers laboratory equipment and services to biopharmaceutica...

More Information about "Ossur North America" on BioPortfolio

We have published hundreds of Ossur North America news stories on BioPortfolio along with dozens of Ossur North America Clinical Trials and PubMed Articles about Ossur North America for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Ossur North America Companies in our database. You can also find out about relevant Ossur North America Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record